MIRA Pharmaceuticals Announces Exclusive Licensing Agreement

– New Chemical Entity Aims to Provide New Treatments for Refractory Depression and Depression with Suicidal Thoughts –
– Ketamir-2 Is Being Developed As a Take Home Alternative to The...

Related Keywords

Canada , Mexico , Adam Kaplin , Erez Aminov , Johns Hopkins Esketamine , Johns Hopkins , Drug Administration , Pharmaceuticals Inc , Janssen Pharmaceuticals Inc , Us Drug Enforcement Administration , Nasdaq , New Chemical Entity Aims , Provide New Treatments , Refractory Depression , Suicidal Thoughts , Take Home Alternative , Revolutionary Drug Spravato , Which Must , Dosed Under Medical Observation , Enforcement Administration , Controlled Substances Act , Chief Scientific Officer , Johns Hopkins Medicine , Principal Investigator , Johns Hopkins Esketamine Clinic , National Network , Depression Center Task Force , Chief Executive Officer , Registration Statement , Janssen Pharmaceuticals , Markets ,